INRLF (Valneva SE) ROE % Adjusted to Book Value : -40.15% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Valneva SE ROE % Adjusted to Book Value?

Valneva SE's ROE % for the quarter that ended in Dec. 2024 was -71.86%. Valneva SE's PB Ratio for the quarter that ended in Dec. 2024 was 1.79. Valneva SE's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -40.15%.

Valneva SE ROE % Adjusted to Book Value Historical Data

The historical data trend for Valneva SE's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE ROE % Adjusted to Book Value Chart

Valneva SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.82

-3.86

-18.29

-11.80

-4.35

Valneva SE Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-18.11	57.46	-21.22	-9.71	-40.15

Competitive Comparison of Valneva SE's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Valneva SE's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Valneva SE's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Valneva SE ROE % Adjusted to Book Value Calculation

Valneva SE's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-7.78%	/	1.79
	=	-4.35%

Valneva SE's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-71.86%	/	1.79
	=	-40.15%

Valneva SE ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Valneva SE's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (OTCPK:INRLF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

VALN:USA 0OB3:UK VLA:France AYJ:Germany AYJ0:Germany AYJ0:Germany AYJ:Germany AYJ:Germany AYJ:Germany VLA:Austria

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.